Skip to main content
Erschienen in: HSS Journal ® 2/2012

01.07.2012 | Original Article

Management Strategy for Symptomatic Bisphosphonate-Associated Incomplete Atypical Femoral Fractures

verfasst von: Anas Saleh, MD, Vishal V. Hegde, BA, Anish G. Potty, MD, Robert Schneider, MD, Charles N. Cornell, MD, Joseph M. Lane, MD

Erschienen in: HSS Journal ® | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Long-term bisphosphonate use has often been associated with atypical femoral fractures. These fractures evolve from incomplete femoral fractures. A previous study demonstrated that the presence of a radiolucent line in an incomplete fracture can indicate a high risk of progression to complete fracture.

Questions/Purposes

The aim of this study is to present a management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. Specific study questions include the following: (1) Is there a difference in the prognosis of these fractures based on the presence or absence of a radiolucent fracture line? (2) Can treatment with teriparatide assist in clinical/radiographic healing of these incomplete fractures? (3) Is there a characteristic biochemical profile in these patients?

Patients and Methods

We retrospectively examined all femur radiographs ordered by the metabolic bone disease service at our hospital between July 1, 2006 and July 1, 2011 and identified 10 patients with a total of 14 incomplete fractures. Nine patients received bisphosphonates for a mean duration of 10 ± 5 years (range, 4–17). The mean follow-up since the time of diagnosis was 20 ± 11 months (range, 6–36 months).

Results

Five fractures did not have a radiolucent fracture line and were treated conservatively with partial weight-bearing restrictions and pharmacologic therapy. All five of these fractures healed with conservative management. Nine fractures had a radiolucent fracture line, and only two of these were treated successfully with conservative management including teriparatide. Six of the eight patients with a radiolucent line elected for surgical prophylaxis after 3 months of conservative management, whereas one patient underwent surgical prophylaxis without a trial of conservative management. Regarding the biochemical profiles, bone turnover markers for our patient cohort were in the lower quartile.

Conclusions

Fractures without a radiolucent line appear to respond to conservative management and not require surgical prophylaxis. Teriparatide treatment may hold promise in promoting healing of these fractures.
Literatur
1.
Zurück zum Zitat Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: A case series. Calcif Tissue Int. 2009;85(1):37–44.PubMedCrossRef Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: A case series. Calcif Tissue Int. 2009;85(1):37–44.PubMedCrossRef
2.
Zurück zum Zitat Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–414.PubMedCrossRef Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–414.PubMedCrossRef
3.
Zurück zum Zitat Banffy MB, Vrahas MS, Ready JE, Abraham JA. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res. 2011;469(7):2028–2034.PubMedCrossRef Banffy MB, Vrahas MS, Ready JE, Abraham JA. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res. 2011;469(7):2028–2034.PubMedCrossRef
4.
Zurück zum Zitat Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): A randomized trial. JAMA. 2006;296(24):2927–2938.PubMedCrossRef Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): A randomized trial. JAMA. 2006;296(24):2927–2938.PubMedCrossRef
5.
Zurück zum Zitat Boden BP, Osbahr DC, Jimenez C. Low-risk stress fractures. Am J Sports Med. 2001;29(1):100–111.PubMed Boden BP, Osbahr DC, Jimenez C. Low-risk stress fractures. Am J Sports Med. 2001;29(1):100–111.PubMed
6.
Zurück zum Zitat Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199.PubMedCrossRef Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199.PubMedCrossRef
7.
Zurück zum Zitat Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. 1997;12(1):6–15.PubMedCrossRef Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. 1997;12(1):6–15.PubMedCrossRef
8.
Zurück zum Zitat Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91(11):2556–2561.PubMedCrossRef Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91(11):2556–2561.PubMedCrossRef
9.
Zurück zum Zitat Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: Subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468(7):1991–1996.PubMedCrossRef Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: Subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468(7):1991–1996.PubMedCrossRef
10.
Zurück zum Zitat Chesnut CH,3 rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med. 2000;109(4):267–276.PubMedCrossRef Chesnut CH,3 rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med. 2000;109(4):267–276.PubMedCrossRef
11.
Zurück zum Zitat Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92(5):679–686.CrossRef Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92(5):679–686.CrossRef
12.
Zurück zum Zitat Deutsch AL, Coel MN, Mink JH. Imaging of stress injuries to bone. radiography, scintigraphy, and MR imaging. Clin Sports Med. 1997;16(2):275–290.PubMedCrossRef Deutsch AL, Coel MN, Mink JH. Imaging of stress injuries to bone. radiography, scintigraphy, and MR imaging. Clin Sports Med. 1997;16(2):275–290.PubMedCrossRef
13.
Zurück zum Zitat Dijkman BG, Sprague S, Schemitsch EH, Bhandari M. When is a fracture healed? radiographic and clinical criteria revisited. J Orthop Trauma. 2010;24 Suppl 1:S76-80.PubMedCrossRef Dijkman BG, Sprague S, Schemitsch EH, Bhandari M. When is a fracture healed? radiographic and clinical criteria revisited. J Orthop Trauma. 2010;24 Suppl 1:S76-80.PubMedCrossRef
14.
Zurück zum Zitat Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int. 1996;59(1):6–11.PubMedCrossRef Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int. 1996;59(1):6–11.PubMedCrossRef
15.
Zurück zum Zitat Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br. 2007;89(3):349–353.PubMedCrossRef Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br. 2007;89(3):349–353.PubMedCrossRef
16.
Zurück zum Zitat Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96(6):1627–1632.PubMedCrossRef Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96(6):1627–1632.PubMedCrossRef
17.
Zurück zum Zitat Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010;468(12):3393–3398.PubMedCrossRef Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010;468(12):3393–3398.PubMedCrossRef
18.
Zurück zum Zitat Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int. 1999;10(5):399–407.PubMedCrossRef Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int. 1999;10(5):399–407.PubMedCrossRef
19.
Zurück zum Zitat Jobke B, Pfeifer M, Minne HW. Teriparatide following bisphosphonates: Initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res. 2009;50(1):46–54.PubMedCrossRef Jobke B, Pfeifer M, Minne HW. Teriparatide following bisphosphonates: Initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res. 2009;50(1):46–54.PubMedCrossRef
20.
Zurück zum Zitat Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: A herald of impending fracture? J Orthop Trauma. 2010;24(2):75–81.PubMedCrossRef Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: A herald of impending fracture? J Orthop Trauma. 2010;24(2):75–81.PubMedCrossRef
21.
Zurück zum Zitat Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury. 2008;39(2):224–231.PubMedCrossRef Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury. 2008;39(2):224–231.PubMedCrossRef
22.
Zurück zum Zitat Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int. 2009;20(8):1353–1362.PubMedCrossRef Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int. 2009;20(8):1353–1362.PubMedCrossRef
23.
Zurück zum Zitat Leung F, Lau TW, To M, Luk KD, Kung AW. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2012; in press. Leung F, Lau TW, To M, Luk KD, Kung AW. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2012; in press.
24.
Zurück zum Zitat Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. the alendronate phase III osteoporosis treatment study group. N Engl J Med. 1995;333(22):1437–1443.PubMedCrossRef Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. the alendronate phase III osteoporosis treatment study group. N Engl J Med. 1995;333(22):1437–1443.PubMedCrossRef
25.
Zurück zum Zitat Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357:nihpa40967. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357:nihpa40967.
26.
Zurück zum Zitat Martin BR. The role of bone remodeling in preventing or promoting stress fractures. In: Burr DB, Milgrom C, eds. Musculoskeletal fatigue and stress fractures. Boca Raton: CRC; 2001:183–202. Martin BR. The role of bone remodeling in preventing or promoting stress fractures. In: Burr DB, Milgrom C, eds. Musculoskeletal fatigue and stress fractures. Boca Raton: CRC; 2001:183–202.
27.
Zurück zum Zitat Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–350.PubMedCrossRef Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–350.PubMedCrossRef
28.
Zurück zum Zitat Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161–168.CrossRef Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161–168.CrossRef
29.
Zurück zum Zitat Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301.PubMedCrossRef Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301.PubMedCrossRef
30.
Zurück zum Zitat Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–1587.PubMedCrossRef Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–1587.PubMedCrossRef
31.
Zurück zum Zitat Schaffler MB. Bone fatigue and remodeling in the development of stress fractures. In: Burr DB, Milgrom C, eds. Musculoskeletal fatigue and stress fractures. Boca Raton: CRC; 2001:161–182. Schaffler MB. Bone fatigue and remodeling in the development of stress fractures. In: Burr DB, Milgrom C, eds. Musculoskeletal fatigue and stress fractures. Boca Raton: CRC; 2001:161–182.
32.
Zurück zum Zitat Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2010;25(11):2267–2294.PubMedCrossRef Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2010;25(11):2267–2294.PubMedCrossRef
33.
Zurück zum Zitat Sloan AV, Martin JR, Li S, Li J. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone. 2010;47(2):235–240.PubMedCrossRef Sloan AV, Martin JR, Li S, Li J. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone. 2010;47(2):235–240.PubMedCrossRef
34.
Zurück zum Zitat Spitz DJ, Newberg AH. Imaging of stress fractures in the athlete. Radiol Clin North Am. 2002;40(2):313–331.PubMedCrossRef Spitz DJ, Newberg AH. Imaging of stress fractures in the athlete. Radiol Clin North Am. 2002;40(2):313–331.PubMedCrossRef
35.
Zurück zum Zitat Tervonen O, Junila J, Ojala R. MR imaging in tibial shaft fractures. A potential method for early visualization of delayed union. Acta Radiol. 1999;40(4):410–414.PubMedCrossRef Tervonen O, Junila J, Ojala R. MR imaging in tibial shaft fractures. A potential method for early visualization of delayed union. Acta Radiol. 1999;40(4):410–414.PubMedCrossRef
36.
Zurück zum Zitat Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93(8):2948–2952.PubMedCrossRef Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93(8):2948–2952.PubMedCrossRef
Metadaten
Titel
Management Strategy for Symptomatic Bisphosphonate-Associated Incomplete Atypical Femoral Fractures
verfasst von
Anas Saleh, MD
Vishal V. Hegde, BA
Anish G. Potty, MD
Robert Schneider, MD
Charles N. Cornell, MD
Joseph M. Lane, MD
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
HSS Journal ® / Ausgabe 2/2012
Print ISSN: 1556-3316
Elektronische ISSN: 1556-3324
DOI
https://doi.org/10.1007/s11420-012-9275-y

Weitere Artikel der Ausgabe 2/2012

HSS Journal ® 2/2012 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.